3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Neuroendocrine Tumors
3
Gastro-enteropancreatic neuroendocrine tumor
2
Pheochromocytoma
1
Paraganglioma
1
Pancreatic Neoplasms
1
Carcinoid Tumor
1
Adenoma, Islet Cell
1
Acromegaly
1
Interventions
lanreotide
1
Tissue Banks
1
Surgical Procedures, Operative
1
Octreotide
1
Observation
1
Dosage Forms
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Acromegaly
×
lanreotide
×
1 year
×
Clear all
NCT05364944
2025-11-17
OXTEND-01
Debiopharm International SA
Phase 1
Terminated
19 enrolled